gilead-sciences

Gilead to lay off one fifth of sales force

pharmafile | April 11, 2019 | News story | Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales 

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents on two of the company’s older drugs.

Gilead will lay off around 150 cardiopulmonary sales representatives as generic versions of the firm’s heart drugs, Letairis and Ranexa, are set to hit the market.

While Letairis and Ranexa brought in $943 million and $758 million, respectively, in 2018 – Ranexa’s patent expires next month while multiple generics have already been approved for Letairis.

Advertisement

The two drugs generated around 8% of Gilead’s overall sales.

In total Gilead has 11,000 employees. The redundancy of 150 tenured sales people has been described as a cost cutting move.  

The decision was first put into motion almost two years ago, according to BioCentury.

Louis Goss

Related Content

Gilead’s HIV treatment meets primary trial endpoint

Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia

Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

Gilead shares phase 3 results from HIV prevention trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …

The Gateway to Local Adoption Series

Latest content